Our lead product, Thera-101, has demonstrated groundbreaking potential in neurological conditions. It has been shown to reduce brain injury caused by stroke, reduce inflammation, promote regeneration and repair of brain tissues, and, most impressively, minimize loss of cognitive and motor function.
The proprietary TheratomeTM technology is a platform with broad application to treat human disease and injury. In addition to brain injury and stroke, Theratome Bio has established a substantial body of preclinical evidence in other indications. We intend to create value with these follow-on indications, and are open to partnering. Areas of collaborative interest include:
- Auto-immune disease
- Chronic neurodegenerative disease
- Ischemic heart disease
- Organ transplant
- Peripheral arterial disease
- Wound healing
Thera-101 is a cell-free biologic drug designed to be administered by IV injection. In contrast to cell therapies, Thera-101 requires no liquid nitrogen storage or special transport conditions (i.e., cryo-genic freezing), nor complicated thawing or administration procedures. Off-the-shelf packaging and storage provide convenience for use inside and outside the hospital setting, including administration on an ambulance. In conditions when time=brain, readily available therapy has more potential to impact outcomes.